AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...
The Cereval acquisition – which was announced around the same time – was one of two made by AbbVie at the end of last year ...
The Big Pharma is also looking to the remaining pipeline from the Cerevel deal. Tavapadon, for example, recently met the ...
Hosted on MSN7d
High-Yield AbbVie Gains Momentum: A 20% Upside Is in SightThe story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...
EDT AbbVie (ABBV) says ‘pleased’ with progress advancing product pipeline Published first on TheFly – the ultimate ...
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback